[ad_1]
 |
| On the 20th, when the number of new coronavirus (Corona 19) infections was recorded, a record 1097, medical staff are collecting samples at a temporary screening clinic in Seoul Plaza, Jung-gu, Seoul. 2020.12.20 / News1 © News1 Reporter Seongcheol Lee |
Pfizer’s new vaccine against coronavirus infection (Corona 19) was launched in major foreign countries such as the United States, and Korea is expected to begin the first vaccination with only the AstraZeneca vaccine.
Since the Ministry of Food and Drug Safety recently initiated a preliminary review of Pfizer’s clinical data, the approval process is expected to accelerate, but due to Pfizer’s supply program to other countries and preparations for storage and distribution in Korea, it is expected to be introduced in Korea only after the second quarter. be be.
According to the Security and Disaster Countermeasures Headquarters on the 21st, the vaccines introduced next year through government pre-purchase negotiations that began in July this year are AstraZeneca, Pfizer, Modena and Janssen, for a total of 34 millions.
Among them, AstraZeneca, which signed the first government contract, promised to supply 10 million vaccines to the Korean government in the first quarter of next year. As AstraZeneca’s phase 3 clinical trial in the United States completes in January, initial volume for 10 million people is expected to arrive in February and March of next year.
Other vaccines are expected to enter Korea after the first quarter of next year. The government plans to sign contracts for 10 million Pfizer vaccines and 4 million Janssen vaccines within this month. In addition, he aims to sign a contract with Modena in January for 10 million people.
In the case of these three companies, the supply of vaccines was promised by signing the purchase contract and confirming the supply, but the delivery deadline has not yet been set as the main contract has not been signed. For this reason, it is difficult to introduce vaccines other than AstraZeneca in the first quarter of next year in Korea.
In fact, Prime Minister Jeong Sye-gyun appeared on KBS1TV ‘Sunday Diagnosis Live’ on the 20th and said: “2 of the 3 companies Pfizer, Janssen and Modena are about to sign the contract, and most of the other companies agree to the terms. ” “The contract is imminent, but we have not received any supply promises in the first quarter,” he said.
Unlike Korea, in the United States, the Pfizer vaccine was approved and vaccinated for the first time. The AstraZeneca vaccine is expected to be approved after January next year when the analysis of the results of phase 3 clinical trials in the United States is announced.
However, in European countries such as the UK, AstraZeneca’s vaccine is being reviewed in advance for approval and approval is expected later this month. The AstraZeneca vaccine is being reviewed ahead of time for approval in Korea, and clinical data will also be received in January, and the review process is expected to accelerate.
In contrast, Pfizer recently submitted all data from Phases 1, 2, and 3 to the Ministry of Food and Drug Safety. It is noted that had the government proceeded quickly with the negotiations prior to the purchase of Pfizer, it could have accelerated the introduction of the Corona 19 vaccine in Korea through a preliminary review.
However, as of yet, a vaccine advance purchase agreement has not been signed with Pfizer, so getting a vaccine from AstraZeneca from February to March is the fastest alternative. It is estimated that around 3 million people will be vaccinated first in Korea because the amount is divided into fourths according to the difference in the production of pharmaceutical companies.
First of all, those who are eligible for vaccination are medical institution workers, group facility residents and workers, the elderly, chronically ill, child and youth education and childcare workers and staff, the former in responding to Corona 19, the police, firefighters and military personnel.
Vaccines for these people will continue through the fourth quarter of next year’s influenza epidemic. Currently, those under 18 years of age and pregnant women who do not have clinical trial data are excluded from the vaccination recommendation, and generally healthy adult males who are not included in the vaccination priority occupation group are also subordinate to vaccination. vaccination.
The Vaccination Committee of the World Health Organization (WHO) also classifies health workers and the elderly at high risk of infection as top priority targets. In the United States, medical personnel and nursing home residents have been given top priority. The UK recommends preferential vaccination for the elderly and workers living in nursing homes, as well as for medical and social health workers aged 80 and over.
Regarding the timing of the national vaccination with the Corona 19 vaccine, Son Young-rae, head of the Strategic Planning Division, said: “We will check the stability as quickly as possible while comprehensively evaluating the stability of the vaccine for Koreans. , the approval process in foreign countries and the use cases. ”
[ad_2]
